Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED90 of remimazolam + remifentanil for procedural sedation in pediatric circumcision
ChiCTR2400088209Phase 4Not yet recruiting
- Sponsor
- Affiliated Women and Children's Hospital of Ningbo University
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam and remifentanil in preputial disorder, sponsored by Affiliated Women and Children's Hospital of Ningbo University. Primary endpoint: MOAA/S score at 1 minute after medication. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
remimazolamremifentanil
03
Conditions
preputial disorder
Beyond the preview
Go deeper on ChiCTR2400088209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088209.